|
1. Biologie
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Bristol-Myers Drops After Cancer Drug Combo Rejected in Europe [Bloomberg]
|
|
|
|
|
|
During
a call discussing the company’s second-quarter results, Chief Executive
Officer Giovanni Caforio said that Bristol-Myers’s combination cancer
treatment had failed to secure additional approval from European
regulators for use in a form of kidney cancer. Adding new indications
for the drugs has been a key part of their growth.
|
|
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018 [EMA]
|
|
|
|
|
|
The
CHMP recommended granting marketing authorisations for four cancer
medicines: Braftovi (encorafenib) and Mektovi (binimetinib), two
medicines to be used in combination in the treatment of patients with
unresectable or metastatic melanoma with a BRAF V600 mutation; Imfinzi
(durvalumab), for the treatment of non-small cell lung cancer and
Verzenios (abemaciclib), for the treatment of locally advanced or
metastatic breast cancer.
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
From Cattle Rancher to ASCO President [Medpage Today]
|
|
|
|
|
|
Steeped
within the world of cancer clinical trials as both a longtime
researcher and cooperative group chair, she knows how much oncology has
learned from the 3% of patients on clinical trials, and wants that
knowledge to expand to the other 97%. She sees such ASCO programs as
CancerLinQ as a way to capture more data about all cancer patients, not
just those on clinical trials.
|
|
|
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|